Literature DB >> 31409584

Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Simona Pagliuca1,2, David Michonneau1,2, Flore Sicre de Fontbrune1, Aurélien Sutra Del Galy1,2, Aliénor Xhaard1, Marie Robin1, Régis Peffault de Latour1,2, Gérard Socie1,2.   

Abstract

Endothelial cell (EC) activation has been suspected of triggering a group of rare and dismal complications that can occur after allogeneic hematopoietic stem cell transplantation (HSCT). Capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy, diffuse alveolar hemorrhage, and idiopathic pneumonia syndrome are the main nosological entities. Post-HSCT endotheliitis can be triggered by chemotherapy, infections, and calcineurin inhibitors, but allogeneic reactivity is claimed to be the common denominator. Endothelial damages are thought to activate several deleterious pathways (proapoptotic, procoagulant, proinflammatory) and can lead to multiorgan failure; however, clinical manifestations of each syndrome overlap, and their relationship with graft-versus-host disease could be minimal. The lack of well-defined diagnostic criteria does not allow for a clear-cut comparison in the current literature. Therapeutic efforts have been made to intercept the pathogenic mechanisms leading to EC dysfunction, but remission rates and survival remain mostly unsatisfactory. In this article, we have reviewed the incidence, clinical features, and treatment approaches of EC activation syndromes, and we plead for the development of internationally accepted standard definitions.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2019        PMID: 31409584      PMCID: PMC6693000          DOI: 10.1182/bloodadvances.2019000143

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  97 in total

1.  Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance.

Authors:  A Limmer; J Ohl; C Kurts; H G Ljunggren; Y Reiss; M Groettrup; F Momburg; B Arnold; P A Knolle
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

Review 2.  Engraftment syndrome following hematopoietic stem cell transplantation.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

3.  Serum levels of soluble adhesion molecules in stem cell transplantation-related complications.

Authors:  Y Matsuda; J Hara; Y Osugi; S Tokimasa; H Fujisaki; K Takai; H Ohta; K Kawa-Ha; S Okada
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

Review 4.  Vascular endothelium: checkpoint for inflammation and immunity.

Authors:  B C Biedermann
Journal:  News Physiol Sci       Date:  2001-04

5.  Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome.

Authors:  H Takatsuka; Y Takemoto; S Yamada; H Wada; S Tamura; Y Fujimori; T Okamoto; A Suehiro; A Kanamaru; E Kakishita
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

6.  Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation.

Authors:  K R Cooke; G R Hill; A Gerbitz; L Kobzik; T R Martin; J M Crawford; J P Brewer; J L Ferrara
Journal:  Transplantation       Date:  2000-07-27       Impact factor: 4.939

7.  Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.

Authors:  K S Bhalla; S W Wilczynski; A M Abushamaa; W P Petros; C S McDonald; J S Loftis; N J Chao; J J Vredenburgh; R J Folz
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

8.  Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation.

Authors:  S A Capizzi; S Kumar; N E Huneke; M A Gertz; D J Inwards; M R Litzow; M Q Lacy; D A Gastineau; U B Prakash; A Tefferi
Journal:  Bone Marrow Transplant       Date:  2001-06       Impact factor: 5.483

9.  Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy.

Authors:  I D Lewis; T DeFor; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2000-09       Impact factor: 5.483

Review 10.  Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation.

Authors:  J Teruya; M Styler; S Verde; D Topolsky; P Crilley
Journal:  J Clin Apher       Date:  2001       Impact factor: 2.821

View more
  20 in total

1.  Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.

Authors:  Hiroyuki Matsui; Yasuyuki Arai; Hiroharu Imoto; Takaya Mitsuyoshi; Naoki Tamura; Tadakazu Kondo; Junya Kanda; Takayuki Ishikawa; Kazunori Imada; Yasunori Ueda; Yusuke Toda; Naoyuki Anzai; Kazuhiro Yago; Masaharu Nohgawa; Akihito Yonezawa; Hiroko Tsunemine; Mitsuru Itoh; Kazuyo Yamamoto; Masaaki Tsuji; Toshinori Moriguchi; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2020-07-14

2.  Noninfectious complications of hematopoietic cell transplantation.

Authors:  Kirsten M Williams
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Massive periorbital edema following hematopoietic stem cell transplantation.

Authors:  Jeannette Y Stallworth; Jonathan C Horton
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-30

4.  Chimerism, the Microenvironment and Control of Leukemia.

Authors:  H Joachim Deeg
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

5.  Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication.

Authors:  Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft
Journal:  Bone Marrow Transplant       Date:  2021-01-30       Impact factor: 5.483

6.  Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.

Authors:  Miki Hashimoto; Hidehiro Itonaga; Yasuhito Nannya; Hirokazu Taniguchi; Yuichi Fukuda; Takafumi Furumoto; Machiko Fujioka; Sachie Kasai; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Yasushi Sawayama; Sunao Atogami; Keisuke Iwasaki; Tomoko Hata; Hiroshi Soda; Yukiyoshi Moriuchi; Koh Nakata; Seishi Ogawa; Yasushi Miyazaki
Journal:  Intern Med       Date:  2019-12-26       Impact factor: 1.271

7.  Perspective: A Framework to Screen Pediatric and Adolescent Hematopoietic Cellular Therapy Patients for Organ Dysfunction: Time for a Multi-Disciplinary and Longitudinal Approach.

Authors:  Ali H Ahmad; Kris M Mahadeo
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

8.  Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation.

Authors:  Jin Wu; Hai-Xia Fu; Yun He; Xiao-Dong Mo; Xiao Liu; Xuan Cai; Ruo-Yun Gui; Hui-Xin Liu; Chen-Hua Yan; Yu-Hong Chen; Ying-Jun Chang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Bone Marrow Transplant       Date:  2021-04-12       Impact factor: 5.483

Review 9.  Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation.

Authors:  Cristina Tecchio; Marco Antonio Cassatella
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

Review 10.  How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Benoît Vandenhove; Lorenzo Canti; Hélène Schoemans; Yves Beguin; Frédéric Baron; Carlos Graux; Tessa Kerre; Sophie Servais
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.